Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Trial Profile

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teprasiran (Primary)
  • Indications Delayed graft function
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Quark Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2018 Results of negative binomial model determining DGF severity difference between groups from subset of donors of QRK006B study presented at the 2018 American Transplant Congress
    • 31 Jul 2014 Results presented at the World Transplant Congress 2014.
    • 01 Jul 2014 According to the Quark Pharmaceuticals media release, results from this trial will be presented at the World Transplant Congress 2014 on 26 - 31 Jul 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top